Quince Therapeutics (QNCX) to Release Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is anticipated to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million for the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Stock Down 1.6 %

Shares of Quince Therapeutics stock opened at $1.24 on Friday. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market cap of $54.56 million, a price-to-earnings ratio of -1.00 and a beta of 0.74. The firm’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.47.

Analyst Upgrades and Downgrades

QNCX has been the topic of several research reports. D. Boral Capital cut their price objective on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Brookline Capital Management assumed coverage on Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target on the stock. Finally, Oppenheimer initiated coverage on Quince Therapeutics in a research note on Monday, March 24th. They set an “outperform” rating and a $10.00 price objective for the company. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $8.00.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.